Company intelligence / Profile preview

Innovative Cardiovascular Solutions

Kalamazoo, Michigan, United Statesprnewswire.com ↗

Ownership: Private
Development stage: Commercial

Overview

The EMBLOK™ Embolic Protection System has shown promising initial results in European clinical studies for capturing and removing embolic debris during TAVR and other left-sided heart procedures. U.S. pivotal trials are being prepared with ongoing discussions with the FDA. The device remains investigational and not yet approved for sale.

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Surgical Medical Devices

Drug pipeline

1 asset

EMBLOK Embolic Protection System

Commercial

Indications: Embolic protection during TAVR

Partnerships

Collaborations with clinical sites in Europe and the U.S. for clinical studies; specific commercial partnerships not disclosed.

Beyond the preview

Go deeper on Innovative Cardiovascular Solutions.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Innovative Cardiovascular Solutions.

Explore the full profile